-+ 0.00%
-+ 0.00%
-+ 0.00%

Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patients With Myeloproliferative Neoplasms

Benzinga·11/04/2025 12:07:54
Listen to the news

Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced an exclusive option agreement with Incyte (Nasdaq:INCY) focused on Prelude's previously undisclosed mutant selective JAK2V617F JH2 inhibitor program in development for patients with myeloproliferative neoplasms (MPNs). Per the agreement, Incyte secures an exclusive option to acquire the JAK2V617F program in exchange for an upfront payment and a strategic equity investment in Prelude, plus potential downstream milestones and royalties.